"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
| Descriptor ID |
D060828
|
| MeSH Number(s) |
E02.319.499 E02.860.500
|
| Concept/Terms |
Induction Chemotherapy- Induction Chemotherapy
- Chemotherapies, Induction
- Chemotherapy, Induction
- Induction Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".
This graph shows the total number of publications written about "Induction Chemotherapy" by people in this website by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 5 | 6 |
| 2012 | 3 | 6 | 9 |
| 2013 | 4 | 7 | 11 |
| 2014 | 4 | 8 | 12 |
| 2015 | 4 | 12 | 16 |
| 2016 | 6 | 9 | 15 |
| 2017 | 10 | 4 | 14 |
| 2018 | 7 | 7 | 14 |
| 2019 | 3 | 9 | 12 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 10 | 11 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 2 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.
-
Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Oct; 31(10):6918-6930.
-
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. Leuk Res. 2024 05; 140:107480.
-
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.
-
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2023 08; 41(8):857-867.
-
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica. 2023 01 01; 108(1):42-47.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):1-7.
-
Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis. Clin Transplant. 2023 01; 37(1):e14836.
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
-
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 09; 97(9):1127-1134.